Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma
Oncology·MeSH: Stomach Neoplasms
4 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| PF-08634404 | Merus N.V. (MRUS) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| PF-08634404 | PFIZER INC (PFE) |
Phase 2/Phase 3(1)
| Drug | Company |
|---|---|
| chemotherapy | PFIZER INC (PFE) |
Phase 4(1)
| Drug | Company |
|---|---|
| Chemotherapy | Merus N.V. (MRUS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma?
BioSniper tracks 4 drugs in development for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma across 2 companies.
How many clinical trials target Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma?
There are 1 clinical trial targeting Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma tracked by BioSniper.
Deep-dive into Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis